Drug Transporter (DT) Information

General Information of DT
DT ID DTD0002
Gene Name ABCC2
Protein Name Multidrug resistance-associated protein 2
Gene ID
1244
UniProt ID
Q92887
TCDB ID
3.A.1.208.2
3D Structure

Modelled DT Structure

Method: homology modeling

Template PDB: 6UY0_A

Identity: 47.93%

Minimized Score: -2889.043 kcal/mol

Detail: Structure Info

Synonyms ABC30; ABCC2; ATP-binding cassette sub-family C member 2; CMOAT; CMOAT1; CMRP; Canalicular multidrug resistance protein; Canalicular multispecific organic anion transporter 1; DJS; MRP2
DT Family ATP-Binding Cassette (ABC) Superfamily
Drug Conjugate Transporter (DCT) Family (ABCC)
Tissue Specificity Expression in the hepatocytes, renal proximal tubule cells, and intestinal epithelia, and expression in the gallbladder, bronchi, and placenta, It is, however, present in brain capillaries of hippocampus specimens from patients with temporal lobe epilepsy, and in malignant tumor cells from renal clear-cell, hepatocellular, ovarian, colorectal, lung, breast, and gastric carcinomas
Function This transporter mediates hepatobiliary excretion of numerous organic anions and may function as a cellular cisplatin transporter.
Disease(s) Chronic myelogenous leukemia [ICD-11: 2A20.0]
Colorectal cancer [ICD-11: 2B91]
Epilepsy [ICD-11: 8A6Z]
Gout [ICD-11: FA25]
Organ transplant rejection [ICD-11: NE84]
Ovarian cancer [ICD-11: 2C73]
Pemphigus vulgaris [ICD-11: EB40.0]
Maintenance of normal sinus rhythm [ICD-11: BC81.3]
Pneumonia [ICD-11: CA40]
Endogenous Substrate(s) Alkaloids; Bilirubin glucuronides; Cysteinyl leukotrienes; E2 17 beta glucuronide; Epipodophyllotosine; Glutahione conjugates; Glutathione dilsulfide; Hepatic canalicular conjugates; Reduced glutathione; Taruochenodeoxycholate sulfate; Taurolithocholate sulfate; Dehydroepiandrosterone sulfate
Variability Data of This Drug Transporter (DT)

Regulatory Variability Data of This DT (VARIDT 3.0)

(α) Microbiota Influence of This DT
Microbiota Influence (MBI)

(β) Post-translational Modification of This DT
Post-translational Modification (PTM)

(γ) Transcriptional Regulation of This DT
Transcriptional Regulation (TSR)

(δ) Epigenetic Regulation of This DT
Epigenetic Regulation (EGR)

(ε) Exogenous Modulation of This DT
Exogenous Modulation (EGM)

Structural Variability Data of This DT (VARIDT 2.0)

(α) Mutation-induced Structural Variation
Mutation-induced Structural Variation (MSV)

(β) Inter-species Structural Differences
Inter-species Structural Differences (ISD)

(γ) Outward/inward-facing Conformation
Outward/inward-facing Conformation (OIC)

(δ) Xenobiotics-regulated Structural Variability
Xenobiotics-regulated Structural Variability (XSV)

General Variability Data of This DT (VARIDT 1.0)

(α) Genetic Polymorphisms of This DT
Genetic Polymorphisms of This DT (GPD)

(β) Disease-specific Protein Abundances of This DT
Disease-specific Protein Abundances of This DT (DPAD)

(γ) Species- and Tissue-specific DT Abundances
Species/Tissue-specific Protein Abundances of This DT (S/TPAD)
Molecular Transporting Profile of This DT

Full List of Drug(s) Transported by This DT

 Approved Drug

 Click to Show/Hide the Full List of Drug:          77 Drugs in Total
Drug Name Highest Status Detail Indication ICD 11 Ref
Acetaminophen
 Approved Drug Info Pain MG30-MG7Z [1]
Acyclovir
 Approved Drug Info Shingles 1.00E+91 [2]
Adefovir
 Approved Drug Info Herpes simplex virus infection 1F00 [3]
Ampicillin
 Approved Drug Info Bacterial infections 1A00-1H0Z [4]
Arsenic trioxide
 Approved Drug Info Acute lymphoblastic leukemia 2B33.0 [5]
Azithromycin
 Approved Drug Info Traveler's diarrhea ME05.1 [6]
Carbamazepine
 Approved Drug Info Epilepsy 8A6Z [7]
Cefadroxil
 Approved Drug Info Gram-positive & negative bacteria infections 1A00-1H0Z [8]
Cefodizime
 Approved Drug Info Bacterial infections 1A00-1H0Z [4]
Ceftriaxone
 Approved Drug Info Pneumonia CA40 [4]
Cerivastatin
 Approved Drug Info Hyperlipidaemia 5C8Z [9]
Cholic acid
 Approved Drug Info Synthesis disorders 5C52.10 [10]
Cidofovir
 Approved Drug Info Cytomegalovirus infections 1D82 [4]
Cisplatin
 Approved Drug Info Testicular cancer 2C80 [11]
Cyclosporine
 Approved Drug Info Xerophthalmia 5B55.Y [12]
Dehydroepiandrosterone sulfate
 Approved Drug Info Dyspareunia GA12 [13]
Dinoprostone
 Approved Drug Info Medical abortion JA00.1 [14]
Docetaxel
 Approved Drug Info Lung cancer 2C25 [15]
Doxorubicin
 Approved Drug Info Leukemia 2A60-2B33 [16]
Enalapril
 Approved Drug Info High blood pressure BA00 [17]
Epirubicin
 Approved Drug Info Node-positive breast cancer 2C60-2C6Z [4]
Erythromycin
 Approved Drug Info Pelvic inflammatory disease GA05 [18]
Estrone sulfate
 Approved Drug Info Menopausal symptoms MF32 [19]
Etoposide
 Approved Drug Info Testicular cancer 2C80 [20]
Ezetimibe
 Approved Drug Info Hypercholesterolemia 5C80.0 [21]
Fluorescein
 Approved Drug Info Ocular disease 9E1Z [22]
Fluorouracil
 Approved Drug Info Stomach cancer 2B72 [23]
Folic acid
 Approved Drug Info Vitamin deficiency 5B55-5B7Z [24]
Gadobenate dimeglumine
 Approved Drug Info CNS imaging XD47Y1 [25]
Gatifloxacin
 Approved Drug Info Bacterial infections 1A00-1H0Z [26]
Gemifloxacin
 Approved Drug Info Bacterial infections 1A00-1H0Z [27]
Glutathione
 Approved Drug Info Human immunodeficiency virus infection 1C62.Z [28]
Glycyrrhizin
 Approved Drug Info Hepatitis C virus infection 1E50.2, 1E51.1 [29]
Grepafloxacin
 Approved Drug Info Chronic bronchitis CA20.1 [30]
Indinavir
 Approved Drug Info Human immunodeficiency virus infection 1C62.Z [31]
Irinotecan
 Approved Drug Info Colorectal cancer 2B91 [32]
Leucovorin
 Approved Drug Info Colorectal cancer 2B91 [33]
Lopinavir
 Approved Drug Info Human immunodeficiency virus infection 1C62.Z [34]
Mesalazine
 Approved Drug Info Recurrent ventricular fibrillation BC71.1 [35]
Methotrexate
 Approved Drug Info Leukemia 2A60-2B33 [36]
Mitoxantrone
 Approved Drug Info Metastatic breast cancer 2C6Y [4]
Mycophenolate mofetil
 Approved Drug Info Pemphigus vulgaris EB40.0 [37]
Mycophenolic acid
 Approved Drug Info Organ transplant rejection NE84 [38]
Nelfinavir
 Approved Drug Info Sars coronavirus infections 1D92 [4]
Nilotinib
 Approved Drug Info Chronic myelogenous leukemia 2A20.0 [39]
Octreotide
 Approved Drug Info Maintenance of normal sinus rhythm BC81.3 [40]
Olamufloxacin
 Approved Drug Info Bacterial infections 1A00-1H0Z [29]
Olmesartan medoxomil
 Approved Drug Info High blood pressure BA00 [41]
Oxaliplatin
 Approved Drug Info Colorectal cancer 2B91 [42]
Paclitaxel
 Approved Drug Info Breast cancer 2C60-2C6Z [43]
Pemetrexed
 Approved Drug Info Malignant pleural mesothelioma 2C26.0 [29]
Pemirolast
 Approved Drug Info Itching of the eye due to allergic conjunctivitis 9A60.02 [29]
Phenobarbital
 Approved Drug Info Seizure 8A68 [44]
Phenytoin
 Approved Drug Info Seizures following neurosurgery 8A6Z [45]
Pitavastatin
 Approved Drug Info Primary hyperlipidemia and mixed dyslipidemia 5C8Z [46]
Pitavastatin calcium
 Approved Drug Info Dyslipidaemias 5C8Z [4]
Pravastatin
 Approved Drug Info Hypercholesterolemia 5C80.0 [47]
Probenecid
 Approved Drug Info Hyperuricaemia 5C55.Y [48]
Raltitrexed
 Approved Drug Info Rectal cancer 2B92 [49]
Regorafenib
 Approved Drug Info Metastatic colorectal cancer 2B91 [50]
Rifampicin
 Approved Drug Info Tuberculosis 1B1Z [51]
Ritonavir
 Approved Drug Info Human immunodeficiency virus infection 1C62.Z [31]
Rosuvastatin
 Approved Drug Info Hypercholesterolemia 5C80.0 [52]
Saquinavir
 Approved Drug Info Human immunodeficiency virus infection 1C62.Z [53]
Sorafenib
 Approved Drug Info Pancreatic cancer 2C10 [54]
Succimer
 Approved Drug Info Lead poisoning NE61 [55]
Sulfasalazine
 Approved Drug Info Rheumatoid arthritis FA20 [56]
Sulfinpyrazone
 Approved Drug Info Arthritis FA5Z [57]
Technetium (99MTC) mebrofenin
 Approved Drug Info Imaging of liver and gallbladder XD47Y1 [4]
Telithromycin
 Approved Drug Info Community acquired pneumonia CA40 [16]
Temocaprilate
 Approved Drug Info High blood pressure BA00 [4]
Temocaprilate
 Approved Drug Info High blood pressure BA00 [3]
Valproic Acid
 Approved Drug Info Epilepsy 8A6Z [3]
Valsartan
 Approved Drug Info High blood pressure BA00 [58]
Vasopressin
 Approved Drug Info Enuresis 6C00 [59]
Vinblastine
 Approved Drug Info Testicular cancer 2C80 [60]
Vincristine
 Approved Drug Info Acute lymphoblastic leukemia 2B33.0 [4]

 Clinical Trial Drug

 Click to Show/Hide the Full List of Drug:          11 Drugs in Total
Drug Name Highest Status Detail Indication ICD 11 Ref
Belotecan
 Phase 3 Drug Info Non-small cell lung cancer 2C25 [29]
Camptothecin
 Phase 3 Drug Info Non-small cell lung cancer 2C25 [3]
Glycocholic acid
 Phase 3 Drug Info Bile acid synthesis defect 5C52.11 [61]
Phenethyl isothiocyanate
 Phase 3 Drug Info Cancer 2A00-2F9Z [62]
5-methyltetrahydrofolate
 Phase 2/3 Drug Info Asthma CA23 [29]
(-)-Epicatechin
 Phase 2 Drug Info Becker muscular dystrophy 8C70.0 [63]
BQ-123
 Phase 2 Drug Info ST-Elevation myocardial infarction BA41.0 [29]
Glutathione-S-S-glutathione
 Phase 2 Drug Info Ovarian cancer 2C73 [64]
SN-38
 Phase 2 Drug Info Colon cancer 2B90.Z [65]
Talinolol
 Phase 1 Drug Info Gastrointestinal motility disorder DE2Z [66]
Tauroursodeoxycholate
 Phase 1 Drug Info Asthma CA23 [67]

 Withdrawn, Discontinued or Preclinical Drug

 Click to Show/Hide the Full List of Drug:            9 Drugs in Total
Drug Name Highest Status Detail Indication ICD 11 Ref
Aminohippuric acid
 Withdrawn Drug Info Renal function tests MG02 [68]
Phenolphthalein
 Withdrawn Drug Info Constipation ME05.0 [69]
Rhodamine 123
 Discontinued in Phase 1 Drug Info Prostate cancer 2C82 [70]
Alpha-Zearalenol
 Preclinical Drug Info Cardiovascular disease BE2Z [71]
Chelerythrine
 Preclinical Drug Info Staphylococcus aureus infection 1C41 [29]
Scutellarin
 Preclinical Drug Info Cerebrovascular ischaemia 8B1Z [72]
Sodium taurocholate
 Preclinical Drug Info Type 2 diabetes 5A11 [73]
Taxifolin
 Preclinical Drug Info Ovarian cancer 2C73 [74]
Sincalide
 Preclinical Drug Info Discovery agent N.A. [19]

Endogenous Metabolites (EMs) Handled by This DT

 Endogenous Metabolites (EMs)

 Click to Show/Hide the Full List of EMs:            8 EMs in Total
EM Name PubChem CID Detail Experimental Material Ref
2-(3,4-dihydroxyphenyl)acetic acid
547
EM Info Identified using people of ABCC2 haplotypes (rs717620, rs3740066, rs2273697) [75]
3,4-dihydroxyphenylglycol
91528
EM Info Identified using people of ABCC2 haplotypes (rs717620, rs3740066, rs2273697) [75]
3-hydroxypropanoic acid
68152
EM Info Identified using people of ABCC2 haplotypes (rs717620, rs3740066, rs2273697) [75]
4-hydroxyhippuric acid
151012
EM Info Identified using people of ABCC2 haplotypes (rs717620, rs3740066, rs2273697) [75]
Caffeic acid
689043
EM Info Identified using people of ABCC2 haplotypes (rs717620, rs3740066, rs2273697) [75]
Caffeine
2519
EM Info Identified using people of ABCC2 haplotypes (rs717620, rs3740066, rs2273697) [75]
Dodecanoic acid
3893
EM Info Identified using people of ABCC2 haplotypes (rs717620, rs3740066, rs2273697) [75]
Resorcinol
5054
EM Info Identified using people of ABCC2 haplotypes (rs717620, rs3740066, rs2273697) [75]

Drug-DT Affinity Assessed by Cell Line

 Approved Drug

 Click to Show/Hide the Full List of Drug:            7 Drugs in Total
Drug Name Highest Status Detail Cell Line Affinity Ref
Etoposide Approved Drug Info Madin-Darby canine kidney cells (MDCKII)-MRP2 Km = 617 microM [20]
Irinotecan Approved Drug Info Bile canalicular membrane vesicles-MRP2 Km = 48.9 microM [65]
Irinotecan Approved Drug Info Madin-Darby canine kidney cells (MDCKII)-MRP2 Km = 90.8 microM [32]
Methotrexate Approved Drug Info Human embryonic kidney cells (HEK293)-MRP2 Km = 480 microM [76]
Olmesartan medoxomil Approved Drug Info LLC-PK1 cells-MRP2 Km = 14.9 microM [41]
Valsartan Approved Drug Info LLC-PK1 cells-MRP2 Km = 30.4 microM [58]
Vinblastine Approved Drug Info Madin-Darby canine kidney cells (MDCKII)-MRP2 Km = 137.3 microM [77]

 Clinical Trial Drug

 Click to Show/Hide the Full List of Drug:            1 Drugs in Total
Drug Name Highest Status Detail Cell Line Affinity Ref
SN-38 Phase 2 Drug Info Bile canalicular membrane vesicles-MRP2 Km = 180 microM [65]

 Withdrawn, Discontinued or Preclinical Drug

 Click to Show/Hide the Full List of Drug:            6 Drugs in Total
Drug Name Highest Status Detail Cell Line Affinity Ref
Aminohippuric acid Withdrawn Drug Info Human embryonic kidney cells (HEK293)-MRP2 Km = 880 microM [68]
Aminohippuric acid Withdrawn Drug Info Madin-Darby canine kidney cells (MDCKII)-MRP2 Km = 2100 microM [78]
Aminohippuric acid Withdrawn Drug Info Spodoptera frugiperda (Sf9) cells-MRP2 Km = 5000 microM [78]
Bilirubin Investigative Drug Info Human embryonic kidney cells (HEK293)-MRP2 Km = 0.7 microM [79]
Bilirubin Investigative Drug Info Human embryonic kidney cells (HEK293)-MRP2 Km = 0.9 microM [79]
Estradiol-17beta-glucuronide Investigative Drug Info Human embryonic kidney cells (HEK293)-MRP2 Km = 7.2 microM [80]
References
1 Effect of acetaminophen on expression and activity of rat liver multidrug resistance-associated protein 2 and P-glycoprotein. Biochem Pharmacol. 2004 Aug 15;68(4):791-8.
2 Gene expression in the human intestine and correlation with oral valacyclovir pharmacokinetic parameters. J Pharmacol Exp Ther. 2003 Aug;306(2):778-86.
3 Pharmacogenetics of membrane transporters: an update on current approaches. Mol Biotechnol. 2010 Feb;44(2):152-67.
4 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
5 MRP2 and acquired tolerance to inorganic arsenic in the kidney of killifish (Fundulus heteroclitus). Toxicol Sci. 2007 May;97(1):103-10.
6 Possible involvement of the drug transporters P glycoprotein and multidrug resistance-associated protein Mrp2 in disposition of azithromycin. Antimicrob Agents Chemother. 2004 Mar;48(3):809-14.
7 A nonsynonymous variation in MRP2/ABCC2 is associated with neurological adverse drug reactions of carbamazepine in patients with epilepsy. Pharmacogenet Genomics. 2010 Apr;20(4):249-56.
8 Oral availability of cefadroxil depends on ABCC3 and ABCC4. Drug Metab Dispos. 2012 Mar;40(3):515-21.
9 Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein. J Pharmacol Exp Ther. 2005 Sep;314(3):1059-67.
10 Multiple pathways for fluoroquinolone secretion by human intestinal epithelial (Caco-2) cells. Br J Pharmacol. 2002 Mar;135(5):1263-75.
11 Lentivirus-mediated RNAi silencing targeting ABCC2 increasing the sensitivity of a human nasopharyngeal carcinoma cell line against cisplatin. J Transl Med. 2008 Oct 4;6:55.
12 Is cyclosporine A transport inhibited by pravastatin via multidrug resistant protein 2? Eur J Clin Pharmacol. 2010 Feb;66(2):153-8.
13 Directional trans-epithelial transport of organic anions in porcine LLC-PK1 cells that co-express human OATP1B1 (OATP-C) and MRP2. Biochem Pharmacol. 2005 Feb 1;69(3):415-23.
14 Multidrug resistance associated protein 2 mediates transport of prostaglandin E2. Liver Int. 2006 Apr;26(3):362-8.
15 Transport of diclofenac by breast cancer resistance protein (ABCG2) and stimulation of multidrug resistance protein 2 (ABCC2)-mediated drug transport by diclofenac and benzbromarone. Drug Metab Dispos. 2009 Jan;37(1):129-36.
16 Involvement of the drug transporters p glycoprotein and multidrug resistance-associated protein Mrp2 in telithromycin transport. Antimicrob Agents Chemother. 2006 Jan;50(1):80-7.
17 Vectorial transport of enalapril by Oatp1a1/Mrp2 and OATP1B1 and OATP1B3/MRP2 in rat and human livers. J Pharmacol Exp Ther. 2006 Jul;318(1):395-402.
18 Effect of ABCC2 (MRP2) transport function on erythromycin metabolism. Clin Pharmacol Ther. 2011 May;89(5):693-701.
19 Human hepatobiliary transport of organic anions analyzed by quadruple-transfected cells. Mol Pharmacol. 2005 Oct;68(4):1031-8.
20 Delineating the contribution of secretory transporters in the efflux of etoposide using Madin-Darby canine kidney (MDCK) cells overexpressing P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), and canalicular multispecific organic anion transporter (cMOAT). Drug Metab Dispos. 2002 Apr;30(4):457-63.
21 Intestinal expression of P-glycoprotein (ABCB1), multidrug resistance associated protein 2 (ABCC2), and uridine diphosphate-glucuronosyltransferase 1A1 predicts the disposition and modulates the effects of the cholesterol absorption inhibitor ezetimibe in humans. Clin Pharmacol Ther. 2006 Mar;79(3):206-17.
22 Phosphoinositide 3-kinase/protein kinase B signaling pathway is involved in estradiol 17-D-glucuronide-induced cholestasis: complementarity with classical protein kinase C. Hepatology. 2010 Oct;52(4):1465-76.
23 Enhancing chemosensitivity in oral squamous cell carcinoma by lentivirus vector-mediated RNA interference targeting EGFR and MRP2. Oncol Lett. 2016 Sep;12(3):2107-2114.
24 Mammalian multidrug-resistance proteins (MRPs). Essays Biochem. 2011 Sep 7;50(1):179-207.
25 Liver Perfusion Modifies Gd-DTPA and Gd-BOPTA Hepatocyte Concentrations Through Transfer Clearances Across Sinusoidal Membranes. Eur J Drug Metab Pharmacokinet. 2017 Aug;42(4):657-667.
26 Uptake and intracellular release kinetics of liposome formulations in glioma cells. Int J Pharm. 2010 Aug 16;395(1-2):251-9.
27 Differential effect of P-gp and MRP2 on cellular translocation of gemifloxacin. Int J Pharm. 2011 Nov 25;420(1):26-33.
28 Oxidative and electrophilic stress induces multidrug resistance-associated protein transporters via the nuclear factor-E2-related factor-2 transcriptional pathway. Hepatology. 2007 Nov;46(5):1597-610.
29 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
30 Fluoroquinolone efflux mediated by ABC transporters. J Pharm Sci. 2008 Sep;97(9):3483-93.
31 Interaction of eight HIV protease inhibitors with the canalicular efflux transporter ABCC2 (MRP2) in sandwich-cultured rat and human hepatocytes. Biopharm Drug Dispos. 2010 Mar;31(2-3):178-88.
32 Intestinal transport of irinotecan in Caco-2 cells and MDCK II cells overexpressing efflux transporters Pgp, cMOAT, and MRP1. Drug Metab Dispos. 2002 Jul;30(7):763-70.
33 Transport of methotrexate, methotrexate polyglutamates, and 17beta-estradiol 17-(beta-D-glucuronide) by ABCG2: effects of acquired mutations at R482 on methotrexate transport. Cancer Res. 2003 Jul 15;63(14):4048-54.
34 Effects of cytochrome P450 3A (CYP3A) and the drug transporters P-glycoprotein (MDR1/ABCB1) and MRP2 (ABCC2) on the pharmacokinetics of lopinavir. Br J Pharmacol. 2010 Jul;160(5):1224-33.
35 Transport studies with 5-aminosalicylate. Eur J Clin Pharmacol. 2006 Oct;62(10):871-5.
36 Dose-dependent disposition of methotrexate in Abcc2 and Abcc3 gene knockout murine models. Drug Metab Dispos. 2011 Nov;39(11):2155-61.
37 Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Eur J Clin Pharmacol. 2007 Dec;63(12):1161-9.
38 C-440T/T-331C polymorphisms in the UGT1A9 gene affect the pharmacokinetics of mycophenolic acid in kidney transplantation. Pharmacogenomics. 2007 Sep;8(9):1127-41.
39 Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties. Br J Pharmacol. 2009 Oct;158(4):1153-64.
40 P-glycoprotein- and mrp2-mediated octreotide transport in renal proximal tubule. Br J Pharmacol. 2000 Jan;129(2):251-6.
41 Multiple human isoforms of drug transporters contribute to the hepatic and renal transport of olmesartan, a selective antagonist of the angiotensin II AT1-receptor. Drug Metab Dispos. 2007 Dec;35(12):2166-76.
42 Multidrug Resistance-Associated Protein 2 (MRP2) Mediated Transport of Oxaliplatin-Derived Platinum in Membrane Vesicles. PLoS One. 2015 Jul 1;10(7):e0130727.
43 Multidrug resistance protein 2 is an important determinant of paclitaxel pharmacokinetics. Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6125-32.
44 Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor. J Biol Chem. 2002 Jan 25;277(4):2908-15.
45 Upregulation of brain expression of P-glycoprotein in MRP2-deficient TR(-) rats resembles seizure-induced up-regulation of this drug efflux transporter in normal rats. Epilepsia. 2007 Apr;48(4):631-45.
46 Involvement of BCRP (ABCG2) in the biliary excretion of pitavastatin. Mol Pharmacol. 2005 Sep;68(3):800-7.
47 Role of transporters in the tissue-selective distribution and elimination of drugs: transporters in the liver, small intestine, brain and kidney. J Control Release. 2002 Jan 17;78(1-3):43-54.
48 MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid. Int J Cancer. 2005 Sep 20;116(5):824-9.
49 Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2. Cancer Res. 1999 Jun 1;59(11):2532-5.
50 Regorafenib is transported by the organic anion transporter 1B1 and the multidrug resistance protein 2. Biol Pharm Bull. 2015;38(4):582-6.
51 Expression and distribution of CYP3A genes, CYP2B22, and MDR1, MRP1, MRP2, LRP efflux transporters in brain of control and rifampicin-treated pigs. Mol Cell Biochem. 2010 Apr;337(1-2):133-43.
52 Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin. Drug Metab Dispos. 2008 Oct;36(10):2014-23.
53 Evidence for two interacting ligand binding sites in human multidrug resistance protein 2 (ATP binding cassette C2). J Biol Chem. 2003 Jun 27;278(26):23538-44.
54 Multidrug resistance protein 2 implicates anticancer drug-resistance to sorafenib. Biol Pharm Bull. 2011;34(3):433-5.
55 MRP2 involvement in renal proximal tubular elimination of methylmercury mediated by DMPS or DMSA. Toxicol Appl Pharmacol. 2009 Feb 15;235(1):10-7.
56 Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting. Am J Physiol Gastrointest Liver Physiol. 2009 Aug;297(2):G371-7.
57 Vinblastine and sulfinpyrazone export by the multidrug resistance protein MRP2 is associated with glutathione export. Br J Cancer. 2000 Aug;83(3):375-83.
58 Involvement of transporters in the hepatic uptake and biliary excretion of valsartan, a selective antagonist of the angiotensin II AT1-receptor, in humans. Drug Metab Dispos. 2006 Jul;34(7):1247-54.
59 Transport function and hepatocellular localization of mrp6 in rat liver. Mol Pharmacol. 2000 Mar;57(3):634-41.
60 Severe hypokalemia due to a possible drug-drug interaction between vinblastine and antiretrovirals in a HIV-infected patient with Hodgkin's lymphoma. Int J STD AIDS. 2017 Oct;28(12):1259-1262.
61 Differential modulation of the human liver conjugate transporters MRP2 and MRP3 by bile acids and organic anions. J Biol Chem. 2003 Jun 27;278(26):23529-37.
62 Transport of dietary phenethyl isothiocyanate is mediated by multidrug resistance protein 2 but not P-glycoprotein. Biochem Pharmacol. 2005 Aug 15;70(4):640-7.
63 Transport and metabolism of the tea flavonoid (-)-epicatechin by the human intestinal cell line Caco-2. Pharm Res. 2001 Oct;18(10):1420-5.
64 Purification of the human apical conjugate export pump MRP2 reconstitution and functional characterization as substrate-stimulated ATPase. Eur J Biochem. 1999 Oct 1;265(1):281-9.
65 Biliary excretion mechanism of CPT-11 and its metabolites in humans: involvement of primary active transporters. Cancer Res. 1998 Nov 15;58(22):5137-43.
66 FDA Drug Development and Drug Interactions
67 Human multidrug resistance protein 2 transports the therapeutic bile salt tauroursodeoxycholate. J Pharmacol Exp Ther. 2007 Feb;320(2):893-9.
68 ATP-dependent para-aminohippurate transport by apical multidrug resistance protein MRP2. Kidney Int. 2000 Apr;57(4):1636-42.
69 Biliary excretion of phenolphthalein sulfate in rats. Pharmacology. 2003 Aug;68(4):177-82.
70 Characterization of rhodamine-123, calcein and 5(6)-carboxy-2',7'-dichlorofluorescein (CDCF) export via MRP2 (ABCC2) in MES-SA and A549 cells. Eur J Pharm Sci. 2011 Aug 17;43(5):359-69.
71 ABCC1, ABCC2 and ABCC3 are implicated in the transepithelial transport of the myco-estrogen zearalenone and its major metabolites. Toxicol Lett. 2009 Oct 28;190(2):215-23.
72 Mechanistic studies on the absorption and disposition of scutellarin in humans: selective OATP2B1-mediated hepatic uptake is a likely key determinant for its unique pharmacokinetic characteristics. Drug Metab Dispos. 2012 Oct;40(10):2009-20.
73 Functional analysis of ABCA8, a new drug transporter. Biochem Biophys Res Commun. 2002 Oct 18;298(1):41-5.
74 Permeation of astilbin and taxifolin in Caco-2 cell and their effects on the P-gp. Int J Pharm. 2009 Aug 13;378(1-2):1-8.
75 Single nucleotide polymorphisms of ABCC2 modulate renal secretion of endogenous organic anions. Biochem Pharmacol. 2017 Sep 15;140:124-138.
76 Interaction of nonsteroidal anti-inflammatory drugs with multidrug resistance protein (MRP) 2/ABCC2- and MRP4/ABCC4-mediated methotrexate transport. J Pharmacol Exp Ther. 2007 Jan;320(1):229-35.
77 Are MDCK cells transfected with the human MRP2 gene a good model of the human intestinal mucosa? Pharm Res. 2002 Jun;19(6):773-9.
78 Contribution of multidrug resistance protein 2 (MRP2/ABCC2) to the renal excretion of p-aminohippurate (PAH) and identification of MRP4 (ABCC4) as a novel PAH transporter. J Am Soc Nephrol. 2004 Nov;15(11):2828-35.
79 Transport of monoglucuronosyl and bisglucuronosyl bilirubin by recombinant human and rat multidrug resistance protein 2. Hepatology. 1999 Aug;30(2):485-90.
80 Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells. Mol Pharmacol. 1999 May;55(5):929-37.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.